Affiliations 

  • 1 Cancer Molecular Pathology, School of Medicine, ​Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia; School of Postgraduate Studies and Research, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 2 School of Medicine, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 3 Cancer Molecular Pathology, School of Medicine, ​Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia. Electronic address: a.lam@griffith.edu.au
  • 4 School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia. Electronic address: sookyee_gan@imu.edu.my
Crit Rev Oncol Hematol, 2016 Jul;103:1-9.
PMID: 27179594 DOI: 10.1016/j.critrevonc.2016.04.006

Abstract

Despite significant medical advancement, nasopharyngeal carcinoma (NPC) remains one of the most difficult cancers to detect and treat where it continues to prevail especially among the Asian population. miRNAs could act as tumour suppressor genes or oncogenes in NPC. They play important roles in the pathogenesis of NPC by regulating specific target genes which are involved in various cellular processes and pathways. In particular, studies on miRNAs related to the Epstein Barr virus (EBV)-encoded latent membrane protein one (LMP1) and EBVmiRNA- BART miRNA confirmed the link between EBV and NPC. Both miRNA and its target genes could potentially be exploited for prognostic and therapeutic strategies. They are also important in predicting the sensitivity of NPC to radiotherapy and chemotherapy. The detection of stable circulating miRNAs in plasma of NPC patients has raised the potential of miRNAs as novel diagnostic markers. To conclude, understanding the roles of miRNA in NPC will identify ways to improve the management of patients with NPC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.